Free Trial

WCM Investment Management LLC Invests $20.23 Million in HealthEquity, Inc. (NASDAQ:HQY)

HealthEquity logo with Medical background

WCM Investment Management LLC purchased a new position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 232,641 shares of the company's stock, valued at approximately $20,230,000. WCM Investment Management LLC owned 0.27% of HealthEquity as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HQY. Pier Capital LLC acquired a new stake in shares of HealthEquity during the fourth quarter worth about $8,024,000. HighTower Advisors LLC lifted its position in HealthEquity by 4.8% during the 4th quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock worth $9,122,000 after acquiring an additional 4,370 shares during the period. Wells Fargo & Company MN lifted its position in HealthEquity by 4.7% during the 4th quarter. Wells Fargo & Company MN now owns 124,940 shares of the company's stock worth $11,988,000 after acquiring an additional 5,594 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of HealthEquity by 24.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock valued at $564,000 after purchasing an additional 1,265 shares during the last quarter. Finally, Geneva Capital Management LLC increased its holdings in shares of HealthEquity by 24.6% in the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock valued at $100,642,000 after purchasing an additional 206,894 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.

HealthEquity Price Performance

Shares of HQY traded down $1.73 on Friday, reaching $99.55. The stock had a trading volume of 627,812 shares, compared to its average volume of 862,960. The firm has a market capitalization of $8.61 billion, a PE ratio of 72.66, a PEG ratio of 1.57 and a beta of 0.49. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average of $99.74 and a 200 day moving average of $98.29. HealthEquity, Inc. has a twelve month low of $65.01 and a twelve month high of $116.65.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.16. The firm had revenue of $330.80 million during the quarter, compared to analysts' expectations of $322.25 million. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. During the same period in the previous year, the firm posted $0.80 earnings per share. Sell-side analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HQY. Royal Bank Of Canada increased their price target on HealthEquity from $112.00 to $117.00 and gave the stock an "outperform" rating in a report on Wednesday, June 4th. Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Barrington Research boosted their price target on shares of HealthEquity from $112.00 to $125.00 and gave the stock an "outperform" rating in a research note on Thursday, June 5th. JMP Securities raised their price objective on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research report on Wednesday, June 4th. Finally, Bank of America lifted their price objective on HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $118.09.

View Our Latest Report on HQY

Insider Buying and Selling at HealthEquity

In other HealthEquity news, EVP Elimelech Rosner sold 58,000 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.56, for a total value of $6,528,480.00. Following the sale, the executive vice president owned 75,689 shares of the company's stock, valued at $8,519,553.84. This represents a 43.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director directly owned 84,969 shares in the company, valued at approximately $6,597,842.85. The trade was a 6.34% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 295,700 shares of company stock worth $32,968,990. 1.50% of the stock is owned by corporate insiders.

HealthEquity Company Profile

(Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Stories

Institutional Ownership by Quarter for HealthEquity (NASDAQ:HQY)

Should You Invest $1,000 in HealthEquity Right Now?

Before you consider HealthEquity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.

While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines